ABN AMRO Bank N.V. Purchases 202,516 Shares of Zoetis Inc. $ZTS

ABN AMRO Bank N.V. increased its position in Zoetis Inc. (NYSE:ZTS) by 63.3% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 522,231 shares of the company’s stock after acquiring an additional 202,516 shares during the quarter. ABN AMRO Bank N.V.’s holdings in Zoetis were worth $75,559,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in ZTS. North Star Asset Management Inc. lifted its holdings in shares of Zoetis by 4.9% during the second quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock worth $225,000 after purchasing an additional 67 shares during the period. Moment Partners LLC increased its holdings in Zoetis by 3.2% in the second quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock valued at $367,000 after purchasing an additional 72 shares during the period. CVA Family Office LLC raised its position in Zoetis by 6.7% during the 2nd quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock worth $183,000 after purchasing an additional 74 shares during the last quarter. Bank of Nova Scotia Trust Co. raised its position in Zoetis by 4.6% during the 2nd quarter. Bank of Nova Scotia Trust Co. now owns 1,692 shares of the company’s stock worth $264,000 after purchasing an additional 74 shares during the last quarter. Finally, Country Club Bank lifted its holdings in Zoetis by 1.5% during the 2nd quarter. Country Club Bank now owns 5,142 shares of the company’s stock worth $803,000 after buying an additional 75 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

Zoetis stock opened at $126.69 on Thursday. The stock has a market capitalization of $55.83 billion, a price-to-earnings ratio of 21.33, a PEG ratio of 2.11 and a beta of 0.96. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $177.40. The stock’s 50 day moving average price is $124.00 and its two-hundred day moving average price is $136.62. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The company had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. During the same quarter in the previous year, the business posted $1.58 EPS. Zoetis’s revenue for the quarter was up .5% compared to the same quarter last year. On average, equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.7%. This is an increase from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend is Tuesday, January 20th. Zoetis’s payout ratio is presently 35.69%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several recent research reports. UBS Group set a $136.00 price target on Zoetis in a research note on Thursday, January 29th. Stifel Nicolaus reduced their target price on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a report on Tuesday, November 18th. Piper Sandler restated a “neutral” rating and set a $135.00 price target (down previously from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. BTIG Research restated a “buy” rating and issued a $160.00 price target on shares of Zoetis in a research report on Wednesday, December 3rd. Finally, HSBC set a $140.00 price objective on shares of Zoetis in a research report on Wednesday, December 10th. Five research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Zoetis presently has a consensus rating of “Hold” and a consensus target price of $152.45.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.